AOB

[la-onda]

American Oriental Bioengineering Reiterated At 'Buy/4,' Target Valuation $6 By Investrend Research Analyst Kipley Lytel, CFA
Monday , April 03, 2006 01:03 ET

(financialwire.net via COMTEX) -- April 3, 2006 (FinancialWire) (Investrend Research Syndicate) American Oriental Bioengineering (AMEX:AOB) has been reiterated at "Buy/4" with a 12-month Target Valuation of $6 in a year-end 4Q Update by Investrend Research analyst Kipley Lytel, CFA.

"Inasmuch as American Oriental Bioengineering demonstrated material operational traction on several fronts in 4QFY05 ' including growth in revenue, gross margin, net working capital and cash flow ' much of the absolute progress was diluted on an earnings per share basis (EPS) due to warrants and the private placement. Hence, the EBIT margin was relatively flat in 4QFY05 at 31.4% compared to 31.2% in the prior period quarter, while EPS also flat lined year-over-year at $0.08/share," said Lytel.

Lytel also stated:

Current assets were substantially bolstered by the new capital infusion with a $57.5M cash balance; which has yet to be deployed towards earnings generation in the form of acquisitions of brand name products, plants and/or distribution sources. Indeed, in the conference call, management indicated their aim to double capacity in FY06. The unique advantages for AOB's business model appears expertise, resources and scale in the high growth dual plant-based pharmaceutical and nutraceutical product category lines.

The company recently evaluated seven (7) target companies for acquisitions based on several criteria, including but not limited to: complement with core plant-based competency and industry; expansion of distribution channels with cross-selling potential; solid brand name; attractive valuation multiples, etc. American Oriental Bioengineering has set the acquisition bar high with the HSPL transaction, which had approximately $3M in revenue and 39% gross margin when purchased and now yields revenue of $16.2M with a 63% gross margin (FY05). The value-added of having expertise and capital combined with synergy of scale offers immense intermediate upside given the universe of potential targets was identified in the conference call as approximately 90 companies that fit the initial acquisition screen.

Management also indicated that it takes about six-months to close a transaction and with 'dead' money sitting in the coffer, it is reasonable to expect a host of acquisitions in FY06. Meanwhile, we anticipate the company to remain profitable and advance margins upward as the scale of the operations is expected to offset the costs/expenses associated with a series of relatively small acquisitions throughout the year.

American Oriental Bioengineering is following an active acquisition-driven growth strategy. Between 2001 and 2005, AOB's revenues were growing at a CAGR of 63%, with most growth occurring in 2003 and 2005, while 2005 showed a 71% year-over-year growth. Excluding the acquisition of HSPL, organic revenues grew 42.5% for 2005 as compared to 2004.

The company's PBP division reported $34.2 million in revenue, up 114.4 percent compared to last year. Growth in this segment was driven by sales increases of 226.7 percent in Shanghuanglian Anti-Virus Powder Injection, 79.8 percent increase in sales of the Cease Enuresis Soft Gel and Patch and a 50.8 percent increase in double grain beverage sales. Sales of PBN products were $20.5 million, an increase of 28.2 percent as compared to last year as the company saw increases in all related products due to increased marketing and distribution.

The company completed the quarter with $57.5 million in cash and cash equivalents, inclusive of the $11.2 million received from calling its class "B" warrants in October, 2005, and the Company's $60 million private placement in December, 2005. The company received the first traunche in connection with its private placement consummated in the fourth quarter resulting in gross proceeds of $33.5 million with the remaining $26.5 million of gross proceeds received by the Company in January 2006.

Net total proceeds received from the private placement in December 2005 and January 2006 were $56.4 million. This compares to $11.4 million in cash as of December 31, 2004. Short-term debt decreased $1.3 million to $3.7 million at the end of 2005 as compared to 2004. During the fourth quarter inventory declined by 53.2 percent and 13.3 percent as compared to the third quarter 2005 and fourth quarter 2004 respectively as the Company improved overall efficiency yielding increased inventory turns and reduced inventory days versus both periods.

During 2005, the company generated $11.6 million in positive cash flow from operations. The company's current ratio as of December 31, 2005, was 8.8-to-1 compared to a current ratio or 2.55 to 1 on December 31, 2004.

[Michael]

Fundamentally, the company earned $0.09 in Q4 2005. If no growth, it will be equal to $0.36 for 2006. At around $5.00, I did not see much risk to own this stock.

Short term, the stock has support at $5.0 then strong support at $4.50.

Resistance is at $5.5 then $6.00

Long term bullish.

I agree Shawfund - Long-term AOB is a great growth story.

The market is unfortunately very shortsighted and until we get some tangible news on acquisitions AOB might drift lower. For now this is the best we have to work with:

The company recently evaluated seven (7) target companies for acquisitions based on several criteria, including but not limited to: complement with core plant-based competency and industry; expansion of distribution channels with cross-selling potential; solid brand name; attractive valuation multiples, etc. American Oriental Bioengineering has set the acquisition bar high with the HSPL transaction, which had approximately $3M in revenue and 39% gross margin when purchased and now yields revenue of $16.2M with a 63% gross margin (FY05). The value-added of having expertise and capital combined with synergy of scale offers immense intermediate upside given the universe of potential targets was identified in the conference call as approximately 90 companies that fit the initial acquisition screen.

Management also indicated that it takes about six-months to close a transaction and with 'dead' money sitting in the coffer, it is reasonable to expect a host of acquisitions in FY06. Meanwhile, we anticipate the company to remain profitable and advance margins upward as the scale of the operations is expected to offset the costs/expenses associated with a series of relatively small acquisitions throughout the year.

The stock tried to rally at the end of trading but was rejected at MA50. Instead we ended with a long legged Doji in the middle of a chart pattern. This clearly indicates that the market don't know where to go from here.

I am sure that the stock will rally when they announce news about a concrete acquisition but as said the market is not very patient so we will keep our stop at 4.56.

[bigdogs99999]

Actually I think that the chart looks like the beginning of 2006 when there was a 15-20% jump.  Anyone following AOB knows that news attending the build-up in $$$ should occur relatively soon - we are already in month 4 of 2006.  I think that the fundamentals have finally caught back up to the share price and will hold....

[Michael]

AOB penetrated our stop briefly before the close and as this was an intra day stop we have sold AOB at 4.56 according to the plan

We will keep following news around AOB's potential acquisitions and if the right opportunity presents itself we might buy AOB back.

[la-onda]

sold yesterday 
today news out:
American Oriental Bioengineering, Inc. Announces Acquisition of Guangxi Lingfeng Pharmaceutical Company (GLP); Acquisition Expands Product Line, Distribution Channels; Adds Complimentary Products in Women's Health Area
Tuesday , April 18, 2006 07:00 ET

HONG KONG, Apr 18, 2006 (BUSINESS WIRE) -- American Oriental Bioengineering, Inc. (AMEX:AOB), a company that produces and distributes a broad range of pharmaceutical and nutraceutical products throughout China, today announced the closing of the acquisition of Guangxi Lingfeng Pharmaceutical Company Limited (GLP), a pharmaceutical company, organized under the laws of China, specializing in manufacturing and distribution of plant-based medicines in China. GLP, based in Hezhou City, Guangxi, China, was founded in 1975. Over the past 30 years, GLP has developed a valuable product portfolio aimed at pediatrics, gynecopathy and the treatment of digestive and respiratory system illnesses.

Pursuant to the agreement, AOB acquired 100% ownership of GLP for a total consideration equal to 2.5 times GLP's prior fiscal year revenue. Based on unaudited financial statements consistent with Chinese GAAP, GLP generated revenue of over $10 million USD with positive net income for the year ended December 31, 2005. The purchase price is approximately $25 million, which consists of approximately $20 million USD in cash (subject to adjustments based on completion of US GAAP audits on GLP financial statements) and 1,200,000 shares of restricted common stock of AOB. Subsequent to the closing today, audited financials of GLP will be filed with the Securities and Exchange Commission within the time frame as stipulated by SEC rules.

AOB expects that the acquisition of GLP will extend AOB's product line into the area of women's health and create synergies between GLP's Jinji Series of drugs aimed to treat gynecological inflammations, such as endometritis, annexitis, and AOB's Cease Enuresis product line for the treatment of bedwetting and nighttime urination, primarily targeted at pregnant and post-pregnant women.

GLP has a portfolio of 70 products and operates a distribution network based in Beijing, which extends across China, with a particularly strong presence in Southern China where AOB has yet to establish a significant distribution network. The production facilities of GLP maintain a Good Manufacturing Practices (GMP) certificate as awarded by the Chinese Government and can produce a broad spectrum of delivery specifications, such as capsules, troches, granules, pills, syrups and tinctures.

Tony Liu, Chairman and Chief Executive Officer of AOB said, "GLP is an established and proven manufacturer of plant-based pharmaceuticals with a valuable brand, an extensive distribution network and the opportunity to capitalize on their under-utilized product portfolio. The Jinji Series of gynecological products will contribute to AOB's position in women's health products, which is a large and rapidly growing market in China."

Mr. Liu continued, "AOB expects to leverage GLP's proprietary product portfolio to improve the breadth of our product offerings. GLP also delivers strength in distribution in southern China where AOB has historically been under-represented. We are extremely excited about this acquisition and the financial and strategic value it represents. We believe, similar to the HSPL acquisition in 2004, GLP possesses both immediate value and tremendous upside potential for AOB and its shareholders."

[bigdogs99999]

AOB has broken out and up from all of its moving averages this week with decent volume.  With the recent acquisition last month which will dramatically increase revenues and looks like it will be accretive (and will also instantly create a new distribution network for existing AOB products) ... I am thinking that the fundamentals of AOB have finally caught up with the stock price and that it is ready for another move. 

[alien41]

Back in AOB.  Closed at $5.32 today.  Earnings come out on Friday.  Wondering if anyone had any thoughts in regards to holding through earnings.  I really like what this stock has to offer but it hasn't been able to break through $6.00.  Thanks in advanced'

Alien

[la-onda]

nice results 

American Oriental Bioengineering, Inc. Announces Revenue and Earnings for the First Quarter 2006; First Quarter Revenues Increase 98% versus Last Year: Net Income Increases 125%, EPS Increases 60%
Friday , May 12, 2006 08:29 ET

HONG KONG, May 12, 2006 (BUSINESS WIRE) -- American Oriental Bioengineering, Inc. (AMEX:AOB):

First Quarter 2006 Highlights:

-- Receipt of the Second Tranche of Proceeds in Connection with the December 2005 private placement

-- Operating margins expand to 33.4%, an improvement of over 2.0% versus 1Q 2005

-- Subsequent to the close of the First Quarter, Company announces the acquisition of GLP

American Oriental Bioengineering, Inc. (AMEX:AOB), an emerging Chinese manufacturer and distributor of plant-based pharmaceutical and nutraceutical products, today announced financial results for the first quarter ending March 31, 2006.

Key Financial Indicators
(All numbers in thousands, except per-share amounts in USD)

                                   Q1 2006  Q1 2005  Percentage Change
Revenues                          $ 19,087  $ 9,653        97.7%
Cost of goods sold                $  6,509  $ 3,628        79.4%
Gross Profit                      $ 12,577  $ 6,025       108.8%
Total Operating Expenses          $  6,194  $ 3,000       106.5%
Income from operations            $  6,383  $ 3,025       111.0%
Net Income                        $  4,917  $ 2,183       125.2%
EPS -- Fully Diluted              $   0.08  $  0.05        60.0%
Diluted Shares                       61.3M    42.7M        43.6%


The US dollar amounts are calculated based on the average conversion rate of US $1 to RMB 8.0436 for the first quarter of 2006 and US $1 to RMB 8.3 for the first quarter of 2005.

First Quarter 2006 Financial Results:

For the first quarter, the Company reported revenues of $19.1 million, an increase of 97.7 percent compared to the $9.7 million reported in the first quarter last year and down 3.5 percent compared to the $19.8 million reported in the fourth quarter of 2005. The increase in revenue as compared to the first quarter of last year is attributable to growth in both the Company's Plant-based Pharmaceutical (PBP) and Plant-based Nutraceutical (PBN) products. During the first quarter of 2006, sales of PBP products increased approximately $6.2 million, or 102.8 percent compared to the same period in 2005. PBP revenues were driven by a 137.9 percent increase in Cease Enuresis Soft Gel and Patch sales and a 101.6 percent increase in Shuanghuanlian Injection Powder sales. PBP revenue growth was also driven by continued strength in Double Ginseng Grain product sales, which increased 57.6 percent from the same period of last year. During the first quarter of 2006, PBN sales increased by $3.3 million or 89.4 percent compared to the same period last year as the Company continued to improve its marketing efforts geared towards educating consumers about the benefits of soy-based peptide products. PBN revenues were driven by a 122.9 percent increase in Soy Peptide Tablets and a 116.2 percent increase in Vitamate Oral Liquid sales.

On a sequential basis PBP revenue increased by 0.4 percent while PBN revenue decreased by 9.6 percent. The overall revenue decline on a sequential basis was due to seasonality, which the Company has experienced in the past, as the fourth quarter is traditionally strongest of the year. The Company's 3.5 percent sequential revenue decline in the first quarter of 2006 compares favorably to the 23.6 percent sequential decline in the first quarter of 2005.

Cost of goods sold were $6.5 million, an increase of 79.4 percent compared to the $3.6 million reported during the first quarter of 2005, resulting in a gross margin of 65.9 percent for the first quarter compared to 62.4 percent for the comparable period last year and 65.2 percent during the fourth quarter of 2005. Gross margins improved in the first quarter as the Company yielded higher efficiencies in its manufacturing processes, particularly versus the year-ago period as further improvements were made on the integration of HSPL.

Selling and marketing expenses increased 159.6 percent to $1.7 million. Advertising expenses increased 173.0 percent to $2.2 million, both compared to the first quarter of last year. Total operating expenses were $6.2 million, an increase of 106.5 percent compared to $3.0 million reported for the same period last year as the Company increased expenses to support operational growth.

Operating income increased to $6.4 million, up 111.0 percent from $3.0 million in the year-ago quarter. Operating margins were 33.4 percent, which improved 2.1 percent from 31.3 in the first quarter of 2005 and up 2.0 percent from 31.4 percent in the fourth quarter 2005. The Company continues to seek opportunities to rationalize costs and reduce inefficiencies to drive greater profitability.

The Company had an effective income tax rate during the quarter of 23.9 percent compared to 25.6 percent last year. This tax is in addition to the Value Added Tax (VAT) of 17.0 percent deducted from the Company's gross revenues each quarter. Net income increased 125.2 percent to $4.9 million or $0.08 per fully diluted share versus net income of $2.2 million or $0.05 per fully diluted share in the same period last year. Fully diluted earnings per share increased 60.0 percent as compared to last year and were flat sequentially despite a 43.6 percent and 18.8 percent increase in shares utilized in this calculation relative to the first quarter of 2005 and the fourth quarter of 2005, respectively.

Commenting on the first quarter of 2006, Mr. Tony Liu, Chairman and CEO of AOB, said, "We are very pleased to report a solid first quarter which resulted in strong revenue and earnings despite what is historically a weaker seasonal quarter. The Company experienced strength across all product lines which reflects the success of our efforts to continue to increase brand awareness and further penetrate underserved and rapidly growing markets throughout China."

Balance Sheet

The Company completed the quarter with $80.9 million in cash and cash equivalents. Cash and cash equivalents increased from $57.5 million during the fourth quarter of 2005 primarily as a result of $3.9 million in positive cash flow from operations and the receipt on January 23, 2006, of the second tranche of net cash proceeds of $25.0 million in connection with the $60.0 million private placement effected in December 2005. Short-term debt totaled $3.7 million and was down $1.4 million versus the year-ago period and unchanged from the fourth quarter of last year. Inventory increased 4.5 percent and 64.5 percent from the first quarter of 2005 and fourth quarter of 2005 respectively to $8.1 million. The increase in inventory was below that of overall sales growth for the first quarter with the increase necessary to support the Company's future growth. The Company continues to have excellent quality receivables with overall Days Sales Outstanding (DSO) unchanged from last year at 45 days. As of March 31, 2006, the Company had a current ratio of 11.24 to 1 as compared to a current ratio of 2.68 to 1 on March 31, 2005.

Mr. Liu continued, "In addition to remarkable organic growth dynamics in our existing products and markets, there continues to be a tremendous opportunity to make strategic and accretive acquisitions in China. While there are other companies that may also have an interest in pursuing these acquisitions, AOB has a unique ability to identify, access and complete the due diligence on these deals and more importantly, possesses the necessary expertise to leverage these opportunities and to successfully integrate the operations of these businesses into AOB. We remain focused on identifying acquisitions that will either enhance our presence in the PBP or PBN marketplace or broaden our distribution network for existing products. The recently completed acquisition of GLP has positioned AOB to accomplish both objectives. The product portfolio we acquired from GLP is complementary to our existing offering in the area of women's health and we believe we can significantly grow GLP revenues by improving the execution of sales and marketing programs and introducing AOB methodologies, which were so successful in the HSPL acquisition. The acquisition of GLP is also important for AOB as it further expands our geographic reach to southern part of China."

Mr. Liu concluded, "We continue to believe that we can meaningfully grow our revenues organically and through acquisitions. We are very well-positioned to execute on this strategy with a talented and experienced management team, a broad and deep existing product portfolio and a healthy balance sheet. We look forward with great anticipation to continued success in 2006."

[alien41]

AOB trading up in pre-market.  Not a big run up pre earnings, maybe they will be able to break 6.00.  We shall see.

Good luck to anyone holding.....Alien

[Se7en]

AOB is up in pre-market because they announced earnings half an hour ago!


http://biz.yahoo.com/bw/060512/20060512005166.html?.v=1
American Oriental Bioengineering, Inc. Announces Revenue and Earnings for the First Quarter 2006
Friday May 12, 8:29 am ET 
First Quarter Revenues Increase 98% versus Last Year: Net Income Increases 125%, EPS Increases 60%


HONG KONG--(BUSINESS WIRE)--May 12, 2006--American Oriental Bioengineering, Inc. (AMEX:AOB - News):
First Quarter 2006 Highlights:

Receipt of the Second Tranche of Proceeds in Connection with the December 2005 private placement
Operating margins expand to 33.4%, an improvement of over 2.0% versus 1Q 2005
Subsequent to the close of the First Quarter, Company announces the acquisition of GLP
American Oriental Bioengineering, Inc. (AMEX:AOB - News), an emerging Chinese manufacturer and distributor of plant-based pharmaceutical and nutraceutical products, today announced financial results for the first quarter ending March 31, 2006.

Key Financial Indicators
(All numbers in thousands, except per-share amounts in USD)

                                   Q1 2006  Q1 2005  Percentage Change
Revenues                          $ 19,087  $ 9,653        97.7%
Cost of goods sold                $  6,509  $ 3,628        79.4%
Gross Profit                      $ 12,577  $ 6,025       108.8%
Total Operating Expenses          $  6,194  $ 3,000       106.5%
Income from operations            $  6,383  $ 3,025       111.0%
Net Income                        $  4,917  $ 2,183       125.2%
EPS -- Fully Diluted              $   0.08  $  0.05        60.0%
Diluted Shares                       61.3M    42.7M        43.6%

The US dollar amounts are calculated based on the average conversion rate of US $1 to RMB 8.0436 for the first quarter of 2006 and US $1 to RMB 8.3 for the first quarter of 2005.

First Quarter 2006 Financial Results:

For the first quarter, the Company reported revenues of $19.1 million, an increase of 97.7 percent compared to the $9.7 million reported in the first quarter last year and down 3.5 percent compared to the $19.8 million reported in the fourth quarter of 2005. The increase in revenue as compared to the first quarter of last year is attributable to growth in both the Company's Plant-based Pharmaceutical (PBP) and Plant-based Nutraceutical (PBN) products. During the first quarter of 2006, sales of PBP products increased approximately $6.2 million, or 102.8 percent compared to the same period in 2005. PBP revenues were driven by a 137.9 percent increase in Cease Enuresis Soft Gel and Patch sales and a 101.6 percent increase in Shuanghuanlian Injection Powder sales. PBP revenue growth was also driven by continued strength in Double Ginseng Grain product sales, which increased 57.6 percent from the same period of last year. During the first quarter of 2006, PBN sales increased by $3.3 million or 89.4 percent compared to the same period last year as the Company continued to improve its marketing efforts geared towards educating consumers about the benefits of soy-based peptide products. PBN revenues were driven by a 122.9 percent increase in Soy Peptide Tablets and a 116.2 percent increase in Vitamate Oral Liquid sales.

On a sequential basis PBP revenue increased by 0.4 percent while PBN revenue decreased by 9.6 percent. The overall revenue decline on a sequential basis was due to seasonality, which the Company has experienced in the past, as the fourth quarter is traditionally strongest of the year. The Company's 3.5 percent sequential revenue decline in the first quarter of 2006 compares favorably to the 23.6 percent sequential decline in the first quarter of 2005.

Cost of goods sold were $6.5 million, an increase of 79.4 percent compared to the $3.6 million reported during the first quarter of 2005, resulting in a gross margin of 65.9 percent for the first quarter compared to 62.4 percent for the comparable period last year and 65.2 percent during the fourth quarter of 2005. Gross margins improved in the first quarter as the Company yielded higher efficiencies in its manufacturing processes, particularly versus the year-ago period as further improvements were made on the integration of HSPL.

Selling and marketing expenses increased 159.6 percent to $1.7 million. Advertising expenses increased 173.0 percent to $2.2 million, both compared to the first quarter of last year. Total operating expenses were $6.2 million, an increase of 106.5 percent compared to $3.0 million reported for the same period last year as the Company increased expenses to support operational growth.

Operating income increased to $6.4 million, up 111.0 percent from $3.0 million in the year-ago quarter. Operating margins were 33.4 percent, which improved 2.1 percent from 31.3 in the first quarter of 2005 and up 2.0 percent from 31.4 percent in the fourth quarter 2005. The Company continues to seek opportunities to rationalize costs and reduce inefficiencies to drive greater profitability.

The Company had an effective income tax rate during the quarter of 23.9 percent compared to 25.6 percent last year. This tax is in addition to the Value Added Tax (VAT) of 17.0 percent deducted from the Company's gross revenues each quarter. Net income increased 125.2 percent to $4.9 million or $0.08 per fully diluted share versus net income of $2.2 million or $0.05 per fully diluted share in the same period last year. Fully diluted earnings per share increased 60.0 percent as compared to last year and were flat sequentially despite a 43.6 percent and 18.8 percent increase in shares utilized in this calculation relative to the first quarter of 2005 and the fourth quarter of 2005, respectively.

Commenting on the first quarter of 2006, Mr. Tony Liu, Chairman and CEO of AOB, said, "We are very pleased to report a solid first quarter which resulted in strong revenue and earnings despite what is historically a weaker seasonal quarter. The Company experienced strength across all product lines which reflects the success of our efforts to continue to increase brand awareness and further penetrate underserved and rapidly growing markets throughout China."

Balance Sheet

The Company completed the quarter with $80.9 million in cash and cash equivalents. Cash and cash equivalents increased from $57.5 million during the fourth quarter of 2005 primarily as a result of $3.9 million in positive cash flow from operations and the receipt on January 23, 2006, of the second tranche of net cash proceeds of $25.0 million in connection with the $60.0 million private placement effected in December 2005. Short-term debt totaled $3.7 million and was down $1.4 million versus the year-ago period and unchanged from the fourth quarter of last year. Inventory increased 4.5 percent and 64.5 percent from the first quarter of 2005 and fourth quarter of 2005 respectively to $8.1 million. The increase in inventory was below that of overall sales growth for the first quarter with the increase necessary to support the Company's future growth. The Company continues to have excellent quality receivables with overall Days Sales Outstanding (DSO) unchanged from last year at 45 days. As of March 31, 2006, the Company had a current ratio of 11.24 to 1 as compared to a current ratio of 2.68 to 1 on March 31, 2005.

Mr. Liu continued, "In addition to remarkable organic growth dynamics in our existing products and markets, there continues to be a tremendous opportunity to make strategic and accretive acquisitions in China. While there are other companies that may also have an interest in pursuing these acquisitions, AOB has a unique ability to identify, access and complete the due diligence on these deals and more importantly, possesses the necessary expertise to leverage these opportunities and to successfully integrate the operations of these businesses into AOB. We remain focused on identifying acquisitions that will either enhance our presence in the PBP or PBN marketplace or broaden our distribution network for existing products. The recently completed acquisition of GLP has positioned AOB to accomplish both objectives. The product portfolio we acquired from GLP is complementary to our existing offering in the area of women's health and we believe we can significantly grow GLP revenues by improving the execution of sales and marketing programs and introducing AOB methodologies, which were so successful in the HSPL acquisition. The acquisition of GLP is also important for AOB as it further expands our geographic reach to southern part of China."

Mr. Liu concluded, "We continue to believe that we can meaningfully grow our revenues organically and through acquisitions. We are very well-positioned to execute on this strategy with a talented and experienced management team, a broad and deep existing product portfolio and a healthy balance sheet. We look forward with great anticipation to continued success in 2006."

[alien41]

Thanks Se7en, I had not seen these results.  Looks alright.

Alien

[jorgegr]

Thought this one was sold on April 11th.

Was it bought again for the 3Stocks of Value or did I miss something

jorgegr

[la-onda]

jorgegr, you are right, sold on the 11th 

BO Alert after execellent results

[Terliso]

I am bringing back AOB on the table... correction is done ready to make new highs
All Indicators are returning bullish

American Oriental reports EPS of $0.08 vs $0.05 yr ago; revs rise 97.7% to $19.1 mln 
American Oriental 1Q Profit Doubles

[nullzero]

yeah AOB looks good on monday.